Trial PaperAnxiety DisordersDepressive DisordersTreatment-Resistant Depression (TRD)Neuroimaging & Brain MeasuresPsilocybin

Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Six months after an open‑label trial, patients with treatment‑resistant depression reported that psilocybin shifted them from disconnection (from self, others and the world) and emotional avoidance towards increased connectedness and acceptance. This suggests psilocybin may relieve depression via mechanisms opposite to those of conventional antidepressant medications and some short‑term talking therapies.

Authors

  • Robin Carhart-Harris
  • David Nutt
  • Rosalind Watts

Published

Journal of Humanistic Psychology
individual Study

Abstract

Objective

To identify patients’ perceptions of the value of psilocybin as a treatment for depression.

Method

Twenty patients enrolled in an open-label trial of psilocybin for treatment-resistant depression participated in a semistructured interview at 6-month follow-up. Thematic analysis was used to identify patients’ experiences of the treatment and how it compared with previous treatments.

Results

Two main change processes were identified in relation to the treatment. The first concerned change from disconnection (from self, others, and world) to connection, and the second concerned change from avoidance (of emotion) to acceptance. A third theme concerned comparison between psilocybin and conventional treatments. Patients reported that medications and some short-term talking therapies tended to reinforce their sense of disconnection and avoidance, whereas treatment with psilocybin encouraged connection and acceptance.

Conclusions

These results suggest that psilocybin treatment for depression may work via paradigmatically novel means, antithetical to antidepressant medications, and some short-term talking therapies.

Available with Blossom Pro

Research Summary of 'Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression'

Introduction

Over the past decade there has been renewed interest in the therapeutic use of classical psychedelics, with modern clinical trials reporting promising safety, tolerability and preliminary efficacy. Watts and colleagues note that much of the recent work has concentrated on conventional symptom-based outcomes, leaving a relative paucity of qualitative investigation into the psychological mechanisms by which psychedelic-assisted treatments might work. The present study was motivated to fill that gap by exploring patients’ own accounts of their experiences following psilocybin treatment for treatment‑resistant depression (TRD), with a view to clarifying candidate psychological processes that might underlie clinical change. This paper reports a thematic, phenomenological analysis of semi‑structured interviews conducted at six months after dosing in the first modern clinical trial of psilocybin for TRD. The core research questions asked what patients experienced during dosing, how they felt in the weeks and months afterwards, what processes of change they identified, and how they compared psilocybin with prior treatments. The study is presented as a qualitative complement to forthcoming formal quantitative and neuroimaging reports from the same trial.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Study Details

Related Clinical Trial

CompletedPhase II

Imperial College London Open-Label Psilocybin Pilot for Treatment-Resistant Depression (Carhart-Harris / Lyons 2016–2018)

Open-label, uncontrolled pilot study of oral psilocybin for treatment-resistant depression at Imperial College London (Front Psychol 2018; Lyons T, Carhart-Harris RL; PMID 30369890; DOI 10.3389/fpsyg.2018.01721; also reported: Carhart-Harris et al. Lancet Psychiatry 2016 n=12, Neuropharmacology 2018 n=20). n=15 TRD patients + 15 healthy controls matched on age/gender/education. Patients: clinically assessed TRD. Intervention: oral psilocybin 10 mg (safety dose) one week before oral psilocybin 25 mg (treatment dose); unblinded, open-label. Outcomes in this paper: future-event forecasting (optimism bias test) at baseline and 1 week post-25 mg session; QIDS-SR depression at baseline and 1 week. Neither patients nor research team masked to treatment. UK regulatory/ethics approval obtained. No CT.gov registration found (searches by PMID, Carhart-Harris, and TRD+psilocybin+UK). Possible ISRCTN or NHS HRA registration not confirmed from available metadata.

Started
Type
interventional
Randomized
No
Registry ID
CARHART-HARRIS-2016-LANCETPSYCH-PSILOCYBIN-TRD-IMPERIAL

References (18)

Papers cited by this study that are also in Blossom

Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

The paradoxical psychological effects of lysergic acid diethylamide (LSD)

Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)

253 cited
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects

Kirchner, K. · Journal of Psychopharmacology (2014)

389 cited
Show all 18 references
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)

420 cited
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial

Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis

Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)

Cited By (159)

Papers in Blossom that reference this study

Investigating Emotional Reactivity in Experienced Users of Psychedelics: a cross-sectional fMRI study

Orłowski, P., Domagalik, A., Bola, M. · Human Brain Mapping (2026)

Trip killers: Addressing a critical knowledge gap in psychedelic research

O’Mahony, B., Harrington, C., Harkin, A. et al. · Journal of Psychopharmacology (2026)

Mixed-methods analysis on psychedelic-augmented meditation experiences from a randomized controlled mindfulness retreat

Schlomberg, J. T. T., Meling, D., Grylka, R. et al. · Scientific Reports (2026)

Therapeutic-Like Context and Relational Support During Psychedelic Use Moderate Links Among Stress, Challenging Experiences, and Psychological Outcomes

Cherniak, A. D., Granqvist, P., Mikulincer, M. et al. · Journal of Psychoactive Drugs (2026)

The combination of exercise and psychedelics for the treatment of major depressive disorder

Fabiano, N., Stubbs, B., Lawrence, D. W. et al. · Discover Mental Health (2026)

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Brett, J., Lea, T., Knock, E. et al. · Addiction (2025)

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Ching, T. H. W., Stahnke, B., Shnayder, S. et al. · Frontiers in Psychiatry (2025)

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis

Kirlić, N., Atli, M., Mistry, S. et al. · Journal of Clinical Psychopharmacology (2025)

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial

Martens, M. A. G., Cunha, B. G., Erritzoe, D. et al. · Translational Psychiatry (2025)

Show all 159 papers
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults

Ermakova, A. O., Dunbar, F., Seynaeve, M. et al. · Scientific Reports (2025)

3 cited
Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation

Suay, D., Aicher, H. D., Singer, B. et al. · Journal of Psychopharmacology (2025)

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

Peck, S. K., Knatz Peck, S., Brewerton, T. D. et al. · Journal of Eating Disorders (2025)

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

Wall, M. B., Demetriou, L., Giribaldi, B. et al. · American Journal of Psychiatry (2025)

Insights on Psychedelics: A Systematic Review of Therapeutic Effects

Kugel, J., Laukkonen, R., Yaden, D. B. et al. · Neuroscience and Biobehavioral Reviews (2025)

Psychedelics Align Brain Activity with Context

Stoliker, D., Novelli, L., Khajehnejad, M. et al. · Biorxiv (2025)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)

Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study

McAlpine, R., Kamboj, S. K. · Scientific Reports (2024)

Acceptance as a possible link between past psychedelic experiences and psychological flexibility

Krabbe, A., Sikka, P., Jylkkä, J. · Scientific Reports (2024)

6 cited
Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey

Stroud, J., Rice, C., Orsini, A. et al. · Psychopharmacology (2024)

Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat

Meling, D., Egger, K., Aicher, H. D. et al. · Journal of Psychopharmacology (2024)

An Integrated theory of false insights and beliefs under psychedelics

McGovern, H., Grimmer, H. J., Doss, M. K. et al. · Communications Psychology (2024)

Neural Mechanisms of Resting-State Networks and the Amygdala underlying the Cognitive and Emotional Effects of Psilocybin

Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)

Psychedelics and the 'inner healer': Myth or mechanism?

Peill, J. M., Marguilho, M., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)

11 cited
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

Levin, A. W., Lancelotta, R., Sepeda, N. D. et al. · PLOS ONE (2024)

48 cited
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)

Psychedelics and sexual functioning: a mixed-methods study

Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)

19 cited
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · Scientific Reports (2024)

Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)

10 cited
Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings

Nicholas, C. R., Horton, D. M., Malicki, J. et al. · Psychedelic Medicine (2023)

When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research

Jacobs, E., Murphy-Beiner, A., Rouiller, I. et al. · Neuroethics (2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder

Heinzerling, K. G., Sergi, K., Linton, M. et al. · Frontiers in Psychiatry (2023)

Psychedelic Intimacy: Altered States of Consciousness in Romantic Relationships

Neubert, J. J., Anderson, K., Mason, N. L. · Psyarxiv (2023)

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)

47 cited
Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials

Noorani, T. N., Bedi, G., Muthukumaraswamy, S. · Psychological Medicine (2023)

21 cited
Life after Ayahuasca: A Qualitative Analysis of the Psychedelic Integration Experiences of 1630 Ayahuasca Drinkers from a Global Survey

Chenhall, R., Sarris, J., Bouso, J. C. et al. · Psychoactives (2023)

Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca

Weiss, B., Wingert, A., Erritzoe, D. et al. · Scientific Reports (2023)

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression

Weiss, B., Ginige, I., Shannon, L. et al. · Psychological Medicine (2023)

The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs

Lake, S., Lucas, P. · Psychedelic Medicine (2023)

Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia

Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)

17 cited
A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Quantitative Analysis

Di Virgilio, V., Minerbi, A., Deol, J. K. et al. · MedRvix (2023)

Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)

4 cited
An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study

Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)

Canalization and plasticity in psychopathology

Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)

Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study

Kaup, K. K., Vasser, M., Tulver, K. et al. · Frontiers in Psychiatry (2023)

Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)

A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Qualitative Analysis of Response Data

Di Virgilio, A., Di Virgilio, V., Minerbi, A. et al. · MedRvix (2023)

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample

Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)

Psilocybin-assisted therapy mediates psycho-social-spiritual change in cancer patients as assessed by the NIH-HEALS

Shnayder, S., Ameli, R., Sinaii, N. et al. · Journal of Affective Disorders (2023)

Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use

Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness

Forstmann, M., Kettner, H. S., Sagioglou, C. et al. · Journal of Psychopharmacology (2023)

“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use

DellaCrosse, M., Pleet, M. M., Morton, E. et al. · PLOS ONE (2022)

21 cited
Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder

Ledwos, N., Rodas, J. D., Husain, M. I. et al. · Journal of Psychopharmacology (2022)

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)

Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy-A systematized review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)

Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience

Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)

35 cited
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis

Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)

Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample

Mellner, C., Dahlen, M., Simonsson, O. · International Journal of Environmental Research and Public Health (2022)

Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)

Awe as a Pathway to Mental and Physical Health

Monroy, M., Keltner, D. · Perspectives on Psychological Science (2022)

106 cited
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Nygart, V., Pommerencke, L. M., Haijen, E. et al. · Journal of Psychopharmacology (2022)

46 cited
Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)

20 cited
Participation in an indigenous Amazonian led ayahuasca retreat associated with increases in nature relatedness - a pilot study

Ruffell, S. G. D., Gandy, S., Tsang, W. et al. · Psyarxiv (2022)

Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions

Cavarra, M., Falzone, A., Ramaekers, J. G. et al. · Frontiers in Psychology (2022)

Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model

Belser, A. B. · Frontiers in Psychology (2022)

57 cited
Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada

Argento, E., Goldenberg, S., Deering, K. et al. · Drug and Alcohol Dependence (2022)

4 cited
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Scientific Reports (2022)

31 cited
Postpartum depression: A role for psychedelics?

Jairaj, C., Rucker, J. · Journal of Psychopharmacology (2022)

New insights into the clinical and nonclinical effects of psychedelic substances: An integrative review.

Forstmann, M., Sagioglou, C. · European Psychologist (2022)

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default

Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)

Self-Care Practices with Psychedelics - A Qualitative Study of Users’ Perspectives

Soares, C. M., Leite, A., Pinto, M. · Journal of Psychoactive Drugs (2022)

Increased global integration in the brain after psilocybin therapy for depression

Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)

162 cited
Psilocybin-Assisted Compassion Focused Therapy for Depression

Pots, W., Chakhssi, F. · Frontiers in Psychology (2022)

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations

Timmermann, C., Watts, R., Dupuis, D. · Transcultural Psychiatry (2022)

95 cited
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)

79 cited
How Psychedelic-Assisted Treatment Works in the Bayesian Brain

Villiger, D. · Frontiers in Psychiatry (2022)

Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers

Thal, S., Engels, L. B., Bright, S. J. · Journal of Humanistic Psychology (2022)

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting

Argento, E., Socias, M. E., Hayashi, K. et al. · International Journal of Drug Policy (2022)

Overcoming epistemic injustices in the biomedical study of ayahuasca: Towards ethical and sustainable regulation

Schenberg, E. E., Gerber, K. · Transcultural Psychiatry (2022)

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience

Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action

Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)

A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development

Whitfield, H. J. · Frontiers in Psychiatry (2021)

Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality

Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L. et al. · Frontiers in Psychology (2021)

Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey

Kuc, J., Kettner, H., Rosas, F. E. et al. · Psychopharmacology (2021)

Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms

Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)

Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample

Lafrance, A., Strahan, E., Bird, B. M. et al. · Journal of Humanistic Psychology (2021)

19 cited
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy

Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)

Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

Do Psychedelics Change Beliefs?

McGovern, H., Leptourgos, P., Hutchinson, B. et al. · Psyarxiv (2021)

The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies

Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)

This Is Something That Changed My Life: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders

Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J. et al. · Frontiers in Psychiatry (2021)

Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics

Earp, B. D., Repantis, D., Langlitz, N. et al. · Frontiers in Psychiatry (2021)

28 cited
Does psychedelic therapy have a transdiagnostic action and prophylactic potential?

Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)

73 cited
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model

Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)

Naturalistic Entheogenics: Précis of Philosophy of Psychedelics

Letheby, C. · Psyarxiv (2021)

2 cited
Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample

Mans, K., Kettner, H., Erritzoe, D. et al. · Frontiers in Psychiatry (2021)

Psychedelics alter metaphysical beliefs

Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)

Psilocybin and MDMA for the treatment of trauma-related psychopathology

Bird, C. I. V., Modlin, N. L., Rucker, J. · International Review of Psychiatry (2021)

An Encounter with the Other: A Thematic Analysis of Accounts of DMT Experiences from a Naturalistic Field Study

Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2021)

Psychedelics and health behaviour change

Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)

Decreased brain modularity after psilocybin therapy for depression

Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Research Square (2021)

Relational Processes in Ayahuasca Groups of Palestinians and Israelis

Roseman, L., Ron, Y., Saca, A. et al. · Frontiers in Pharmacology (2021)

30 cited
Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)

28 cited
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review

Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)

60 cited
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties

Sumner, R. L., Chacko, E., Mcmillan, R. et al. · Journal of Psychopharmacology (2021)

51 cited
Psychedelic Communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness

Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)

157 cited
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice

Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)

55 cited
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)

Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

65 cited
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD

Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)

108 cited
Acute and subacute psychoactive effects of Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): retrospective reports

Schmidt, T. T., Reiche, S., Hage, L. T. et al. · Scientific Reports (2020)

9 cited
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)

Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)

Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation

Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)

82 cited
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)

Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism

Van Mulukom, V., Patterson, R. E., Van Elk, M. · Psychopharmacology (2020)

Ethics and ego dissolution: the case of psilocybin

Smith, W. R., Sisti, D. · Journal of Medical Ethics (2020)

A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding

Madsen, M. K., Fisher, P. M., Stenbæk, D. S. et al. · European Neuropsychopharmacology (2020)

Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications

O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)

Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Reviewing the potential of psychedelics for the treatment of PTSD

Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance

Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)

Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings

Forstmann, M., Yudkin, D. A., Prosser, A. M. B. et al. · PNAS (2020)

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Mertens, L. J., Wall, M. B., Roseman, L. et al. · Journal of Psychopharmacology (2020)

155 cited
Neuropharmacological modulation of the aberrant bodily self through psychedelics

Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)

The use of the psychological flexibility model to support psychedelic assisted therapy

Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)

From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner

Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)

131 cited
Modulation of Social Cognition via Hallucinogens and “Entactogens”.

Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)

Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science

Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)

Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory

Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

Psychedelic drugs-a new era in psychiatry?

Nutt, D. J. · Dialogues in Clinical Neuroscience (2019)

Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD

Barone, W., Beck, J., Mitsunaga-Whitten, M. et al. · Journal of Psychoactive Drugs (2019)

46 cited
How do psychedelics work?

Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

More realistic forecasting of future life events after psilocybin for treatment-resistant depression

Lyons, T., Carhart-Harris, R. L. · Frontiers in Psychology (2018)

49 cited
Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Schenberg, E. E. · Frontiers in Pharmacology (2018)

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)

Effects of psilocybin therapy on personality structure

Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)

219 cited
The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity

Hartogsohn, I. · Frontiers in Human Neuroscience (2018)

Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology

Moroz, M., Carhart-Harris, R. L. · IEEE Explore (2018)

6 cited
The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions

Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)

The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

213 cited
Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression

Lyons, T., Carhart-Harris, R. L. · Journal of Psychopharmacology (2018)

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation

Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in
Patients’ accounts of increased “Connectedness”... — Research Summary & Context | Blossom